NASDAQ:PRLD Prelude Therapeutics (PRLD) Stock Price, News & Analysis $5.30 -0.17 (-3.02%) Closing price 03:59 PM EasternExtended Trading$5.30 +0.00 (+0.09%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Prelude Therapeutics Stock (NASDAQ:PRLD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Prelude Therapeutics alerts:Sign Up Key Stats Today's Range$5.19▼$5.4650-Day Range$3.83▼$6.6352-Week Range$0.98▼$6.83Volume151,465 shsAverage Volume426,173 shsMarket Capitalization$422.54 millionP/E RatioN/ADividend YieldN/APrice Target$7.67Consensus RatingHold Company Overview Prelude Therapeutics Incorporated is a clinical-stage precision medicine company focused on the discovery and development of small molecule therapies for genetically defined oncology targets. By leveraging a chemical biology approach, the company aims to deliver targeted treatments that address key drivers of cancer cell growth and survival. Prelude’s pipeline emphasizes novel inhibitors designed to engage molecular pathways validated by both preclinical and clinical evidence. Among Prelude’s lead programs is PRT2527, a selective PI3K‐alpha/delta inhibitor in Phase 1 clinical trials for solid tumors harboring PIK3CA and other pathway mutations. The company’s second clinical-stage asset, PRT543, is a first-in-class, reversible inhibitor of protein arginine methyltransferase 5 (PRMT5) under evaluation for hematologic malignancies and solid tumors. Prelude is also advancing preclinical candidates targeting KRAS mutations and additional oncogenic drivers to build a diversified portfolio of precision oncology assets. Headquartered in Cambridge, Massachusetts, Prelude Therapeutics collaborates with academic institutions, biopharmaceutical partners and contract research organizations to support global clinical trial efforts. Its integrated research and development capabilities span medicinal chemistry, structural biology, translational pharmacology and biomarker-driven clinical strategy, accelerating the progression of targeted cancer therapies toward the clinic. Since its founding in 2017, Prelude has concentrated on delivering therapies for patient populations with high unmet medical need. With a management team boasting extensive oncology drug development, regulatory and commercial experience, the company seeks to bring differentiated precision medicines to individuals with hard-to-treat and treatment-resistant malignancies worldwide.AI Generated. May Contain Errors. Read More Prelude Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScorePRLD MarketRank™: Prelude Therapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 655th out of 906 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingPrelude Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialPrelude Therapeutics has a consensus price target of $7.67, representing about 42.9% upside from its current price of $5.37.Amount of Analyst CoveragePrelude Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Prelude Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Prelude Therapeutics is -7.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Prelude Therapeutics is -7.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrelude Therapeutics has a P/B Ratio of 4.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Prelude Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.41% of the float of Prelude Therapeutics has been sold short.Short Interest Ratio / Days to CoverPrelude Therapeutics has a short interest ratio ("days to cover") of 9.75.Change versus previous monthShort interest in Prelude Therapeutics has recently increased by 4.00%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPrelude Therapeutics does not currently pay a dividend.Dividend GrowthPrelude Therapeutics does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.67 News SentimentPrelude Therapeutics has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Prelude Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for PRLD on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Prelude Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Prelude Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders49.20% of the stock of Prelude Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions79.72% of the stock of Prelude Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Prelude Therapeutics' insider trading history. Receive PRLD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prelude Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRLD Stock News HeadlinesPrelude Therapeutics (NASDAQ:PRLD) Upgraded at Wall Street ZenSeptember 6 at 1:13 AM | americanbankingnews.comPrelude Therapeutics (NASDAQ:PRLD) Stock Rating Lowered by Wall Street ZenAugust 31, 2026 | americanbankingnews.comThis looks like plywood. It's not.AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more electricity than an entire office building. One new chip, which looks more like a piece of plywood than a processor, delivers similar performance on a fraction of the power. Tech investing veteran George Gilder says that efficiency gap could decide who wins the next stage of AI. Gilder has identified three companies positioned around this power breakthrough, calling them the Trillion Dollar Triangle.September 8 at 1:00 AM | Eagle Publishing (Ad)Prelude Therapeutics: A Prognosis After Year-Long RallyAugust 23, 2026 | seekingalpha.comPrelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateAugust 11, 2026 | markets.businessinsider.comPrelude TherapeuticsJuly 14, 2026 | fool.comPrelude Therapeutics Incorporated (PRLD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 10, 2026 | seekingalpha.comEarnings Beat: Prelude Therapeutics Incorporated (NASDAQ:PRLD) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsMay 16, 2026 | finance.yahoo.comSee More Headlines PRLD Stock Analysis - Frequently Asked Questions How have PRLD shares performed this year? Prelude Therapeutics' stock was trading at $2.90 at the start of the year. Since then, PRLD stock has increased by 85.0% and is now trading at $5.3650. How were Prelude Therapeutics' earnings last quarter? Prelude Therapeutics Incorporated (NASDAQ:PRLD) released its quarterly earnings results on Tuesday, August, 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.06. The company had revenue of $5.70 million for the quarter, compared to analyst estimates of $5.70 million. When did Prelude Therapeutics IPO? Prelude Therapeutics (PRLD) raised $150 million in an initial public offering on Friday, September 25th 2020. The company issued 8,325,000 shares at $17.00-$19.00 per share. Morgan Stanley, Goldman Sachs and BofA Securities served as the underwriters for the IPO. Who are Prelude Therapeutics' major shareholders? Prelude Therapeutics' top institutional investors include BlackRock Inc. (2.26%), ADAR1 Capital Management LLC (1.13%), Connor Clark & Lunn Investment Management Ltd. (0.16%) and Bank of New York Mellon Corp (0.09%). Insiders that own company stock include David P Bonita, Orbimed Advisors Llc, Krishna Vaddi, Krishna Vaddi, Andrew Combs and Bryant David Lim. View institutional ownership trends. How do I buy shares of Prelude Therapeutics? Shares of PRLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Prelude Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Prelude Therapeutics investors own include Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Visa (V) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/11/2026Today9/08/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 PRLD's financial health is in the Green zone, according to TradeSmith. PRLD has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PRLD CIK1678660 Webwww.preludetx.com Phone302-467-1280FaxN/AEmployees120Year Founded2016Price Target and Rating Average Price Target for Prelude Therapeutics$7.67 High Price Target$9.00 Low Price Target$6.00 Potential Upside/Downside+42.9%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$99.50 million Net MarginsN/A Pretax Margin-338.98% Return on Equity-75.35% Return on Assets-44.39% Debt Debt-to-Equity RatioN/A Current Ratio4.07 Quick Ratio4.07 Sales & Book Value Annual Sales$12.14 million Price / Sales35.27 Cash FlowN/A Price / Cash FlowN/A Book Value$1.09 per share Price / Book4.92Miscellaneous Outstanding Shares79,800,000Free Float40,540,000Market Cap$428.13 million OptionableOptionable Beta0.97 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:PRLD) was last updated on 9/8/2026 by MarketBeat.com Staff. From Our PartnersThis looks like plywood. It's not.AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...Eagle Publishing | SponsoredWhat Is A Roth Conversion, And How Do I Set One Up?A Roth conversion moves money from a traditional IRA or employer plan into a Roth IRA, triggering income tax t...SmartAsset | SponsoredThis weekend trading strategy could change your MondaysEvery Monday, trader Tim Sykes opens his account to potential profits as high as $8,780, $9,177, even $16,000....Tim Sykes | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredMusk just exposed the crack in his empireSpaceX's IPO raised approximately $85.7 billion in gross proceeds. Days later, the company revealed its combin...The Oxford Club | SponsoredThey're not buying gold. They're buying this.Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...Behind the Markets | SponsoredSpaceX pays a 10X launch penaltySpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One unde...Freedom Financial | SponsoredThe Closest Thing to a Virtual AI Monopoly Wall Street Is IgnoringA little-known company may be building the closest thing to a virtual AI monopoly that Wall Street has yet to ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prelude Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Prelude Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
